Sanofi SA has expanded a collaboration with CytoReason Ltd, the Israeli technology company, to include inflammatory bowel disease (IBD) in a project that uses artificial intelligence to discover novel disease targets. The two companies have been working together since 2021, initially to identify targets for treating asthma.
IBD describes disorders of tissues in the digestive tract. It includes ulcerative colitis, which involves inflammation of the lining of the large intestine and rectum, and Crohn’s disease, involving inflammation of the lining of the digestive tract.